Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cannabidiol for prevention of acute graft-versus-host disease after allogeneic HSCT
ACTRN12619000623190Phase 2Recruiting
- Sponsor
- Kalytera Therapeutics Israel
- Start
- Jun 2018
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of cannabidiol in Acute Graft-Versus-Host Disease (aGvHD) (3 cohorts), sponsored by Kalytera Therapeutics Israel. Primary endpoints: Pharmacokinetic profile of repeat doses of cannabidiol and Safety and tolerability of repeat doses of cannabidiol for prevention of acute graft-versus-host disease. Started Jun 2018; status: recruiting.
02
Drugs
cannabidiol
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on ACTRN12619000623190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619000623190.